Trials / Completed
CompletedNCT02519413
Tecfidera Lymphocyte Chart Review
A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 483 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other than CD4+ and CD8+ T cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dimethyl fumarate | delayed release capsules |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2015-08-10
- Last updated
- 2016-08-26
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02519413. Inclusion in this directory is not an endorsement.